Evidence map›Paper›PMID 35749108›Full record

ArticleTranslational vision science & technology2022

A Screening Tool for Self-Evaluation of Risk for Age-Related Macular Degeneration: Validation in a Spanish Population.

Alfredo García-Layana, Maribel López-Gálvez, José García-Arumí, Luis Arias, Alfredo Gea-Sánchez, Juan J Marín-Méndez, Onintza Sayar-Beristain, Germán Sedano-Gil, Tariq M Aslam, Angelo M Minnella and 3 more

Abstract read
In one paragraph

Article in Translational vision science & technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alfredo García-LayanaRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain.
Maribel López-GálvezRed Temática de Investigación Cooperativa Sanitaria en Enfermedades Oculares (Oftared), Instituto de Salud Carlos III, Madrid, Spain.
José García-ArumíDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Spain.
Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, University of Barcelona, Barcelona, Spain.
Alfredo Gea-SánchezPreventive Medicine and Public Health, School of Medicine, University of Navarra, Pamplona, Spain.
Juan J Marín-MéndezDatbow SL, Navarra, Spain.
Onintza Sayar-BeristainNNBi 2020 SL, Beriáin, Navarra, Spain.
Germán Sedano-GilNNBi 2020 SL, Beriáin, Navarra, Spain.
Tariq M AslamSchool of Pharmacy and Optometry, University of Manchester and Manchester Royal Eye Hospital, Manchester, UK.
Angelo M MinnellaUOC Oculistica, Università Cattolica del S. Cuore, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
Isabel López IbáñezDepartment of Family and Community Medicine, Centro de Salud Nápoles y Sicilia, Valencia, Spain.
José M de Dios HernándezDepartment of Family and Community Medicine, Centro de Salud La Alamedilla, Salamanca, Spain.
Johanna M SeddonDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The objectives of this study were the creation and validation of a screening tool for age-related macular degeneration (AMD) for routine assessment by primary care physicians, ophthalmologists, other healthcare professionals, and the general population. Methods: A simple, self-administered questionnaire (Simplified Théa AMD Risk-Assessment Scale [STARS] version 4.0) which included well-established risk factors for AMD, such as family history, smoking, and dietary factors, was administered to patients during ophthalmology visits. A fundus examination was performed to determine presence of large soft drusen, pigmentary abnormalities, or late AMD. Based on data from the questionnaire and the clinical examination, predictive models were developed to estimate probability of the Age-Related Eye Disease Study (AREDS) score (categorized as low risk/high risk). The models were evaluated by area under the receiving operating characteristic curve analysis. Results: A total of 3854 subjects completed the questionnaire and underwent a fundus examination. Early/intermediate and late AMD were detected in 15.9% and 23.8% of the patients, respectively. A predictive model was developed with training, validation, and test datasets. The model in the test set had an area under the curve of 0.745 (95% confidence interval [CI] = 0.705-0.784), a positive predictive value of 0.500 (95% CI = 0.449-0.557), and a negative predictive value of 0.810 (95% CI = 0.770-0.844). Conclusions: The STARS questionnaire version 4.0 and the model identify patients at high risk of developing late AMD. Translational Relevance: The screening instrument described could be useful to evaluate the risk of late AMD in patients >55 years without having an eye examination, which could lead to more timely referrals and encourage lifestyle changes.

Indexed as

Macular DegenerationRetinal DrusenDiagnostic Self EvaluationFollow-Up StudiesHumansRisk Factors

Identifiers

PMID35749108
PMCPMC9234358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.